ABBVIE

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD)

Phase 1

Active, not recruiting

Conditions: Generalized Anxiety Disorder (GAD)
Bipolar Disorder (BPD)
Healthy Volunteers

Interventions: Drug: Placebo for ABBV-932
Drug: ABBV-932

First Posted Date: 2023-09-06

Last Posted Date: 2024-10-26

Lead Sponsor: AbbVie

Target Recruit Count: 72

Registration Number: NCT06024239

Locations: 🇺🇸
Collaborative Neuroscience Research CNS /ID# 260270, Los Alamitos, California, United States
🇺🇸
Acpru /Id# 255945, Grayslake, Illinois, United States
🇺🇸
Hassman Research Institute Marlton Site /ID# 260271, Marlton, New Jersey, United States

An Observational Study to Assess Change in Disease Activity and Adverse Events in Adolescent and Adult Participants With Moderate to Severe Active Crohn's Disease (CD) in Japan

Recruiting

Conditions: Crohn's Disease

First Posted Date: 2023-09-05

Last Posted Date: 2024-12-03

Lead Sponsor: AbbVie

Target Recruit Count: 240

Registration Number: NCT06023030

Locations: 🇯🇵
Osaka Metropolitan University Hospital /ID# 273559, Osaka-City, Osaka, Japan
🇯🇵
Anjou Kousei Hospital /ID# 261872, Anjo-shi, Aichi, Japan
🇯🇵
Handa City Hospital /ID# 270446, Handa, Aichi, Japan

and more 68 locations

A Study to Assess Adverse Events and Effectiveness of HAC 20L Injections in Adult Participants for the Treatment of Nasolabial Folds

Phase 2

Active, not recruiting

Conditions: Nasolabial Folds

Interventions: Device: HAC 20L
Other: No-Treatment Control

First Posted Date: 2023-08-31

Last Posted Date: 2024-07-11

Lead Sponsor: AbbVie

Target Recruit Count: 61

Registration Number: NCT06018987

Locations: 🇩🇪
Dermatologische Gemeinschaftspraxis Mahlow /ID# 232366, Blankenfelde-Mahlow, Brandenburg, Germany
🇩🇪
Privatpraxis Dr. Hilton & Partner /ID# 231401, Duesseldorf, Nordrhein-Westfalen, Germany
🇩🇪
CRS Clinical Research Services Berlin GmbH /ID# 240390, Berlin, Germany

and more 7 locations

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

Phase 3

Recruiting

Conditions: Alopecia Areata

Interventions: Drug: Upadacitinib
Drug: Placebo

First Posted Date: 2023-08-25

Last Posted Date: 2024-12-12

Lead Sponsor: AbbVie

Target Recruit Count: 1500

Registration Number: NCT06012240

Locations: 🇺🇸
Dermatologist of Central States (DOCS) Clinical Research - Springfield /ID# 266746, Springfield, Ohio, United States
🇬🇧
Royal Sussex County Hospital /ID# 257912, Brighton, East Sussex, United Kingdom
🇺🇸
Total Skin and Beauty Dermatology Center /ID# 259539, Birmingham, Alabama, United States

and more 264 locations

A Study to Assess Pharmacokinetics, Safety, and Tolerability of ABBV-903 in Healthy Japanese and Han Chinese Participants

Phase 1

Terminated

Conditions: Healthy Volunteers

Interventions: Drug: Placebo for ABBV-903
Drug: ABBV-903

First Posted Date: 2023-08-24

Last Posted Date: 2023-11-13

Lead Sponsor: AbbVie

Target Recruit Count: 24

Registration Number: NCT06009237

Locations: 🇺🇸
Anaheim Clinical Trials LLC /ID# 257033, Anaheim, California, United States

ELAPR002f Injectable Gel in the Treatment of Atrophic Acne Scars

Phase 3

Recruiting

Conditions: Atrophic Acne Scars

Interventions: Other: Saline Active Control
Device: ELAPR002f Injectable Gel

First Posted Date: 2023-08-16

Last Posted Date: 2024-08-09

Lead Sponsor: AbbVie

Target Recruit Count: 156

Registration Number: NCT05995340

Locations: 🇨🇦
Alberta DermaSurgery Centre /ID# 243168, Edmonton, Alberta, Canada
🇨🇦
Dermetics Cosmetic Dermatology /ID# 227469, Burlington, Ontario, Canada
🇨🇦
The Center For Dermatology /ID# 227470, Richmond Hill, Ontario, Canada

and more 9 locations

A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease

Phase 3

Recruiting

Conditions: Crohn's Disease

Interventions: Drug: Risankizumab

First Posted Date: 2023-08-16

Last Posted Date: 2024-12-05

Lead Sponsor: AbbVie

Target Recruit Count: 110

Registration Number: NCT05995353

Locations: 🇨🇦
London Health Sciences Center- University Hospital /ID# 258598, London, Ontario, Canada
🇺🇸
Phoenix Children's Hospital /ID# 255766, Phoenix, Arizona, United States
🇺🇸
Arkansas Children's Hospital /ID# 255762, Little Rock, Arkansas, United States

and more 55 locations

A Study to Assess the Mass Balance of [14C] ABBV-903 in Healthy Male Participants Following Single Oral Dose Administration

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: ABBV-903

First Posted Date: 2023-08-16

Last Posted Date: 2023-10-26

Lead Sponsor: AbbVie

Target Recruit Count: 7

Registration Number: NCT05995366

Locations: 🇺🇸
Fortrea Clinical Research Unit Inc. /ID# 253962, Madison, Wisconsin, United States

Expanded Access to ABBV-400

Conditions: Non-Small Cell Lung Cancer

First Posted Date: 2023-08-09

Last Posted Date: 2024-04-03

Lead Sponsor: AbbVie

Registration Number: NCT05982873

Observational Study of Adult Participants With Diabetic Macular Edema and Suboptimal Response to Anti-Vascular Endothelial Growth Factor Treated With Dexamethasone Intravitreal Implant

Recruiting

Conditions: Diabetic Macular Edema

First Posted Date: 2023-08-07

Last Posted Date: 2024-11-25

Lead Sponsor: AbbVie

Target Recruit Count: 327

Registration Number: NCT05978622

Locations: 🇨🇳
Tongji Hospital /ID# 270275, Wuhan, Hubei, China
🇩🇪
MVZ der Klinik Dardenne GmbH Makulazentrum /ID# 269798, Bonn, Nordrhein-Westfalen, Germany
🇬🇷
University General Hospital Attikon /ID# 257957, Athens, Attiki, Greece

and more 49 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy